The discussion explores how basal and reflex tears differ and why composition impacts sustained eye comfort.

Coave Therapeutics has announced its lead gene therapy program, CoTx-10, for the treatment of retinal vascular diseases, such ...

Harrow has completed the acquisition of Melt Pharmaceuticals, which includes product candidates MELT-210, MELT-300, and ...

Foundation Fighting Blindness has granted public access to de-identified 4-year data from individuals participating in RUSH2A ...

The trial is a phase 1/2 open-label, ascending-dose study of the safety and efficacy of OPGx-LCA5. Recently, the company ...

Apellis Pharmaceuticals recently announced post hoc analysis data of the GALE extension study. This new data is the result of ...

The central theme was moving beyond a lens-centric approach to vision, historically the foundation of presbyopia research, ...

The timeline for the proposed Alcon acquisition of STAAR Surgical has once again been extended as STAAR announced amendments ...

Advanced imaging technologies like intraoperative OCT and heads-up displays enhance surgical precision and patient outcomes ...

A new treatment is presented that eliminates the root cause of the disease and restores ocular surface health.

A study reveals that cryopreserved amniotic membrane enhances recovery and reduces infection risk in post-corneal ...

The US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) from Outlook Therapeutics for ONS-5010 (bevacizumab-vikg) for the treatment of wet age-related ...